Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31303197 | 0.88 | MEN1 (0.44) | PLA2G2CMAPK1MEN1KMT2AASAH1 | |
| SCHEMBL15948706 | 0.85 | EPHX1 (0.37) | DAGLACNR1CYP1A2POLBFASN | |
| SCHEMBL15685416 | 0.84 | EPHX1 (0.37) | — | |
| SCHEMBL15948876 | 0.83 | CTSK (0.36) | — | |
| SCHEMBL17972404 | 0.83 | PLA2G2A (0.44) | PLA2G2A | |
| SCHEMBL17972403 | 0.81 | PLA2G2A (0.45) | DAGLACNR1PLA2G2CPLA2G2A | |
| SCHEMBL17174995 | 0.81 | CNR1 (0.36) | DAGLACNR1PLA2G2CPLA2G2ACYP3A4 | |
| SCHEMBL15381137 | 0.78 | SPHK1 (0.39) | DAGLATP53CYP1A2CYP2D6MAPT | |
| SCHEMBL17682895 | 0.76 | LMNA (0.35) | DAGLATP53CYP1A2CYP2D6MAPT | |
| SCHEMBL20019591 | 0.75 | SPHK1 (0.40) | DAGLACYP2C9CYP2C19TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| US-20150291646-A1 | METHOD OF PREPARATION OF ALPHA GALACTOSYL CERAMIDES COMPOUNDS | ABIVAX (FR) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | DAGLA 2952/4885CNR1 4011/4885PLA2G2C 1444/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | DAGLA 4492/4885CNR1 1314/4885PLA2G2C 599/4885 |
| US-20150291646-A1 | METHOD OF PREPARATION OF ALPHA GALACTOSYL CERAMIDES COMPOUNDS | UGCG, GBA1, MAN2B1 | DAGLA 248/4885CNR1 719/4885PLA2G2C 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.